Clinical characteristics of patients with AML
| Patient . | Sample source . | Blasts, % . | Cytogenetics . | Treatment and responses at the time of sampling . |
|---|---|---|---|---|
| 1 | BM | 89 | 46,XX | Prior CR with idarubicin + Ara-C, relapse |
| 2 | BM | 91 | 46,XY, del(12)(p11.2p13)[7],46,XY,t(2;5)(p11.2;q11.2), del(16)(q13)[3],46,XY,del(3)(q21q27),add(12)(p13),add(22)(q13)[3], 46,XY,der(17)t(11;17)(q12;p11.1)[2],46,XY,del(6)(p21.1p25), del(12)(p11.2p13),add(17)(p11.1) [1],46,XY[2] | Prior CR with idarubicin + Ara-C, relapse, prior CR with decitabine, relapse, resistant to troxacitabine and 5-azacitidine |
| 3 | BM | 83 | 46,XX, inv(16)(p13.1q22) | Newly diagnosed, no treatment |
| 4 | PB | 58 | 46,XX | Newly diagnosed, no treatment |
| 5 | PB | 76 | 46,XX, del(6)(p23), add(14)(p11.2) | Achieved CR with clofarabine and low-dose Ara-C then relapsed |
| 6 | PB | 84 | 45,XY, −7 | Prior CR with clofarabine and low-dose Ara-C, relapse |
| 7 | BM | 77 | 46,XY[30] | Resistant to MGCD-0103 + azacytidine |
| 8 | PB | 66 | 46,XX,t(5;7)(q34;p13)[17],46,XX,t(1;8)(p22;q22)[1],46,XX[2] | Prior CR with idarubicin + Ara C, relapse; prior CR with Mylotarg, relapse |
| 9 | BM | 81 | 46,XX[20] | Newly diagnosed, no treatment |
| 10 | BM | 91 | 45,XY,del(3q),−7 [12] | Newly diagnosed, no treatment |
| 11 | PB | 63 | 46,XY[20] | Newly diagnosed, no treatment |
| 12 | PB | 85 | 46,XY,t(9;11)(p22;q23)[20] | Newly diagnosed, no treatment |
| Patient . | Sample source . | Blasts, % . | Cytogenetics . | Treatment and responses at the time of sampling . |
|---|---|---|---|---|
| 1 | BM | 89 | 46,XX | Prior CR with idarubicin + Ara-C, relapse |
| 2 | BM | 91 | 46,XY, del(12)(p11.2p13)[7],46,XY,t(2;5)(p11.2;q11.2), del(16)(q13)[3],46,XY,del(3)(q21q27),add(12)(p13),add(22)(q13)[3], 46,XY,der(17)t(11;17)(q12;p11.1)[2],46,XY,del(6)(p21.1p25), del(12)(p11.2p13),add(17)(p11.1) [1],46,XY[2] | Prior CR with idarubicin + Ara-C, relapse, prior CR with decitabine, relapse, resistant to troxacitabine and 5-azacitidine |
| 3 | BM | 83 | 46,XX, inv(16)(p13.1q22) | Newly diagnosed, no treatment |
| 4 | PB | 58 | 46,XX | Newly diagnosed, no treatment |
| 5 | PB | 76 | 46,XX, del(6)(p23), add(14)(p11.2) | Achieved CR with clofarabine and low-dose Ara-C then relapsed |
| 6 | PB | 84 | 45,XY, −7 | Prior CR with clofarabine and low-dose Ara-C, relapse |
| 7 | BM | 77 | 46,XY[30] | Resistant to MGCD-0103 + azacytidine |
| 8 | PB | 66 | 46,XX,t(5;7)(q34;p13)[17],46,XX,t(1;8)(p22;q22)[1],46,XX[2] | Prior CR with idarubicin + Ara C, relapse; prior CR with Mylotarg, relapse |
| 9 | BM | 81 | 46,XX[20] | Newly diagnosed, no treatment |
| 10 | BM | 91 | 45,XY,del(3q),−7 [12] | Newly diagnosed, no treatment |
| 11 | PB | 63 | 46,XY[20] | Newly diagnosed, no treatment |
| 12 | PB | 85 | 46,XY,t(9;11)(p22;q23)[20] | Newly diagnosed, no treatment |
CR indicates complete remission.